Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LBPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLBPHLongboard Pharmaceuticals$59.98$59.88$27.35▼$60.03$2.34B11.30 million shsN/AMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLBPHLongboard Pharmaceuticals0.00%0.00%0.00%0.00%+87.97%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLBPHLongboard Pharmaceuticals0.1801 of 5 stars1.20.00.00.00.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLBPHLongboard Pharmaceuticals 2.38Hold$63.005.04% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLBPHLongboard PharmaceuticalsN/AN/AN/AN/A$1.67 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLBPHLongboard Pharmaceuticals-$54.42M-$2.23N/AN/AN/AN/A-33.03%-30.90%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLBPHLongboard PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLBPHLongboard PharmaceuticalsN/A15.9715.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLBPHLongboard Pharmaceuticals63.28%Insider OwnershipCompanyInsider OwnershipLBPHLongboard Pharmaceuticals4.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLBPHLongboard Pharmaceuticals2039.05 million37.23 millionOptionableLBPH HeadlinesRecent News About These CompaniesH Lundbeck A/S (HLUNAC.XD)February 9, 2025 | finance.yahoo.comLundbeck drops in on epilepsy drug with $2.6bn Longboard bidJanuary 27, 2025 | pharmaphorum.comPH. Lundbeck A/S (HLUN-A.CO)December 18, 2024 | finance.yahoo.comLongboard Pharmaceuticals' SWOT analysis: bexicaserin potential drives stock outlookDecember 18, 2024 | investing.comLundbeck acquires all outstanding shares of Longboard PharmaDecember 5, 2024 | msn.comBright Minds initiated at outperform by Baird, Longboard takeover citedNovember 26, 2024 | msn.comHold Rating for Longboard Pharmaceuticals Amidst Acquisition Uncertainty and Speculative RisksNovember 13, 2024 | markets.businessinsider.comLongboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)November 12, 2024 | finance.yahoo.comLongboard Pharmaceuticals Advances Neurological TreatmentsNovember 9, 2024 | markets.businessinsider.comLongboard Pharmaceuticals Inc (LBPH) Stock: Unveiling Its Hidden StrengthsNovember 7, 2024 | bovnews.comBLongboard Pharmaceuticals HSR waiting period expires for Lundbeck dealNovember 7, 2024 | msn.comLongboard Pharmaceuticals granted Orphan Drug Designation for bexicaserinNovember 5, 2024 | markets.businessinsider.comWhy Did Longboard Pharmaceuticals Inc (LBPH) Stock See 74.58% Surge in the Last 90 Days?November 2, 2024 | bovnews.comBLongboard Pharmaceuticals Inc options imply 0.8% move in share price post-earningsNovember 1, 2024 | markets.businessinsider.comLongboard Pharmaceuticals Inc (LBPH) Stock Sees Market Value Hit $2.33 billion: What Are the Implications?October 31, 2024 | bovnews.comBLONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc. - LBPHOctober 31, 2024 | businesswire.comLongboard Pharmaceuticals Inc (LBPH) Stock: Beyond the Surface of Its Performance?October 24, 2024 | bovnews.comBSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBPH and ARC on Behalf of ShareholdersOctober 17, 2024 | globenewswire.comHC Wainwright & Co. Downgrades Longboard Pharmaceuticals (LBPH)October 17, 2024 | msn.comRandall Kaye Sells 16,667 Shares of Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) StockOctober 17, 2024 | insidertrades.comLBPH Company DescriptionsLongboard Pharmaceuticals NASDAQ:LBPHLongboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
